Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of California, San Francisco
Genentech, Inc.
Jonsson Comprehensive Cancer Center
Tempest Therapeutics
MacroGenics
Xencor, Inc.
Carisma Therapeutics Inc
Inhibrx Biosciences, Inc
Eli Lilly and Company
Pliant Therapeutics, Inc.
Weill Medical College of Cornell University
University of California, San Francisco
University of Florida
Cantargia AB
Fate Therapeutics
Xencor, Inc.
Advaxis, Inc.
Eisai Inc.
University of Utah